Arcus Biosciences, Inc. Current Liabilities
Arcus Biosciences, Inc. (RCUS) had Current Liabilities of $198.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $198.00M.
- 2026-03-31: Liabilities, Current $209.00M.
- 2025-12-31: Liabilities, Current $231.00M.
- 2025-09-30: Liabilities, Current $235.00M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $198.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $209.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $231.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $235.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $210.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $192.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $226.00M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $215.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $199.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $204.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $184.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $200.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $180.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $179.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $193.00M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $177.18M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $164.02M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $161.25M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $166.00M 10-K · filed 2023-02-28 | $166.08M 10-K · filed 2022-02-23 |
| 2021-09-30 | $142.87M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $130.37M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $132.06M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $121.67M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $162.87M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $40.02M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $21.00M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $22.71M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $21.06M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $26.51M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $19.00M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $16.93M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $16.61M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $16.38M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $14.26M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $12.73M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |